

NKR1_ADHD børn og unge_PICO 7_Methylphenidate

Characteristics of studies

Characteristics of included studies

Abikoff 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ahmann 1993

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Armstrong 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	

Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Arnold 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ashare 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Barkley 1989

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Barkley 1991

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Barkley 2000

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Bedard 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ben 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Biederman 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Bliznakova 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Blum 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Borcherding 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brams 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brams 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brown 1984a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brown 1985

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brown 1988

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Brown 1991

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Buitelaar 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Bukstein 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Butter 1983

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Carlson 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Carlson 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Castellanos 1997

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Chacko 2005

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Childress 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Childress 2017

Methods	Study design: Randomized controlled trial Study grouping: Parallel group
Participants	Baseline Characteristics Included criteria: Excluded criteria: Pretreatment:
Interventions	Intervention Characteristics
Outcomes	<i>ADHD kernesymptomer, observatør/kliniker bedømt, SKAMP-Combined scores,</i> ● Outcome type: ContinuousOutcome ● Lower=better
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Judgement Comment: Described as a randomized study, unclear how
Allocation concealment (selection bias)	Unclear risk	Judgement Comment: Described as a double-blinded study, unclear how
Blinding of participants and personnel (performance bias)	Unclear risk	Judgement Comment: Described as a double-blinded study, unclear how
Blinding of outcome assessment (detection bias)	Unclear risk	Judgement Comment: Described as a double-blinded study, unclear how
Incomplete outcome data (attrition bias)	Low risk	Judgement Comment: Dropouts accounted for
Selective reporting (reporting bias)	Low risk	Judgement Comment: Matches study protocol
Other bias	Low risk	Judgement Comment: No other apparent sources of bias

Chronis 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	

Other bias	Unclear risk
------------	--------------

Coghill 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Coghill 2013

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Connor 2000

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Cook 1993

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Corkum 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Cox 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Douglas 1986

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Douglas 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

DuPaul 1996

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Duric 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Döpfner 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Epstein 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Fabiano 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Findling 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Findling 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Findling 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Findling 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Fine 1993

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Firestone 1981

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Fitzpatrick 1992a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Flapper 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Forness 1992

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Froehlich 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gadow 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gadow 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gadow 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gadow 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Garfinkel 1983

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gonzalez-Heydrich 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gorman 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Green 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Greenhill 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Greenhill 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Grizenko 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Gruber 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Hale 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Heriot 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Hicks 1985

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Hoepfner 1997

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Horn 1991

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ialongo 1994

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Jacobi-Polishook 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Jensen 1999 (MTA)

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Johnston 1988

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kaplan 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kelly 1989

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kent 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kent 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Klorman 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kolko 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Kollins 2006 (PATS)

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Konrad 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Konrad 2005

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Leddy 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lehmkuhl 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lijffijt 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lin 2014

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lopez 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lufi 1997

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Lufi 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Manos 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Martins 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

McBride 1988a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

McGough 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

McInnes 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Moshe 2012

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Muniz 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Murray 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Musten 1997

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Newcorn 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Newcorn 2017

Methods	Study design: RCT Study grouping: parallel group
Participants	<p>Baseline Characteristics</p> <p>Intervention</p> <ul style="list-style-type: none"> ● Gender: 74 % male ● Age: 130 (29) months ● Previously treated with ADHD medicine: 0 ● Number of participants treated with ADHD medicine: 0 <p>Control</p> <ul style="list-style-type: none"> ● Gender: 66 % male ● Age: 138 (28) months ● Previously treated with ADHD medicine: 0 ● Number of participants treated with ADHD medicine: 0 <p>intervention 2</p> <ul style="list-style-type: none"> ● Gender: ● Age: ● Previously treated with ADHD medicine: ● Number of participants treated with ADHD medicine: <p>Overall</p> <ul style="list-style-type: none"> ● Gender: 70 % male ● Age: 134 (28) months ● Previously treated with ADHD medicine: 0 ● Number of participants treated with ADHD medicine: 0 <p>Included criteria: Eligible participants were required to weigh [79.5 lb, have a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) primary ADHD diagnosis, a baseline ADHD-RS-IV total score < 28, and screening and baseline blood pressure values that did not exceed the 90th percentile for age, sex, and height based on US Centers for Disease Control and Prevention (CDC) guidelines. If currently being treated, participants were required to not be completely satisfied with their current ADHD therapy, as judged by the investigator at the baseline assessment; this criterion reflects the ethical requirement to not discontinue treatment in individuals exhibiting a satisfactory response to their current therapy. The participant and the participant's parent/legally authorized representative were required to provide informed assent and consent and to be willing and able to comply with study requirements.</p> <p>Excluded criteria: Participants were excluded if they had a current controlled or uncontrolled comorbid Axis I or II psychiatric diagnosis (except oppositional defiant disorder, which was allowed), with significant symptoms requiring treatment or contraindicating lisdexamfetamine or OROS-MPH treatment. Comorbid psychiatric diagnoses were established using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Life-time Version - Diagnostic Interview [13]. Participants were excluded if they were considered a suicide risk by the investigator, had previously made a suicide attempt, or were currently demonstrating active suicidal ideation. Additional exclusion criteria were underweight (less than the third percentile) or overweight (97th percentile) based on CDC body mass index (BMI) standards for age and sex; a medical or psychiatric condition that could confound safety assessments or increase participant risk; personal or family cardiovascular history or a clinically significant electrocardiogram (ECG) finding; history of suspected substance abuse or dependence (excluding nicotine) or a lifetime history of amphetamine, cocaine, or stimulant abuse and/or dependence; concomitant use of medications with central nervous system effects that could potentially affect study performance; documented allergy or hypersensitivity to amphetamine or methylphenidate; prior failed response to methylphenidate or amphetamine therapy (because it is not ethical to include individuals who do not have a reasonable expectation of deriving benefit from treatment); participation in another clinical study within 30 days before screening.</p>

Interventions	•
Outcomes	<p><i>Alvorlige bivirkninger-totalt</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome <p><i>ADHD-RS total score_Adfærdsforstyrrelser, forældre bedømt</i></p> <ul style="list-style-type: none"> ● Outcome type: ContinuousOutcome <p><i>Søvnforstyrrelse</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome <p><i>Frafald pga. bivirkninger</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome <p><i>Appetitforstyrrelse</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome ● Reporting: Fully reported ● Direction: Lower is better ● Data value: Endpoint <p><i>vægttab</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome ● Reporting: Fully reported ● Data value: Endpoint
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "Two randomized, double-blind, multicenter, parallel-group studies (one flexible-dose, one forced-dose) with placebo reference arms were conducted." Quote: "At the start of double-blind treatment, participants were randomized (2:2:1) using an IWRS to once-daily treatment with lisdexamfetamine 70 mg/day, OROS-MPH 72 mg/day, or placebo, respectively."
Allocation concealment (selection bias)	Unclear risk	Judgement Comment: Insufficient information on allocation concealment
Blinding of participants and personnel (performance bias)	Low risk	Quote: "To maintain blinding, treatments were over-encapsulated and identical in appearance; participants were also instructed to take one capsule from two separate bottles."
Blinding of outcome assessment (detection bias)	Low risk	Judgement Comment: Bias should be equal distributed however some of the outcomes are "self-reported"
Incomplete outcome data (attrition bias)	Low risk	Quote: "missing data were imputed using last observation carried forward." Judgement Comment: Flowchart with clear description of dropout has been provided
Selective reporting (reporting bias)	Low risk	Quote: "[ClinicalTrials.gov: NCT01552915;]" Quote: "(ClinicalTrials.gov: NCT01552902;)" Judgement Comment: The study appears to be free from selective outcome reporting
Other bias	Low risk	Judgement Comment: The study appears to be free from other sources of bias

Nikles 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Oesterheld 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Overtom 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Palumbo 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pearson 2013

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 1989

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 1990a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 1993a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 2001a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 2005

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pelham 2014

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Perez-Alvarez 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pliszka 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pliszka 2000

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pliszka 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Pliszka 2017

Methods	Study design: Randomized controlled trial Study grouping: Parallel group
Participants	<p>Baseline Characteristics</p> <p>MMPH delayed and extended release</p> <ul style="list-style-type: none"> ● Age in years (SD): 9.6 (1.79) ● Male %: 67.9 ● % on medication: <p>Control</p> <ul style="list-style-type: none"> ● Age in years (SD): 9.0 mean ● Male %: 72.5 ● % on medication: <p>Included criteria: Primary diagnosis of ADHD, according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria (American Psychiatric Association 2013), was required and confirmed using the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) (Sheehan et al. 2010). Other inclusion criteria included, but were not limited to, ADHD Rating Scale-IV (ADHD-RS-IV) score \geq 90th percentile for age and gender and \geq 26 at baseline (DuPaul et al. 1998); Clinical Global Impressions of Severity (CGI-S) score \geq 4 at baseline (Guy 1976); Conners' Global Index-Parent (CGI-P) score $>$ 10 at baseline (Conners 1989); at least a partial clinical response to MPH as judged by the site investigator; EMF impairment and/or difficulties performing a morning routine of \geq 30 minutes in duration occurring between 6:00 and 9:00am; and body weight \geq 20 kg</p> <p>Excluded criteria: Exclusion criteria included, but were not limited to, a history of or current medical condition or laboratory result that could either jeopardize participant safety or interfere with study participation; history of psychosis, bipolar disorder, anorexia nervosa, bulimia, or suicide attempt; current depression, anxiety, conduct disorder, substance use disorder, or other significant psychiatric conditions; history of severe allergic reaction or intolerance to MPH; and use of medication for psychiatric conditions other than ADHD, including antidepressants, mood stabilizers, and antipsychotics</p>

	Pretreatment:
Interventions	<p>Intervention Characteristics</p> <p>MMPH delayed and extended release</p> <ul style="list-style-type: none"> ● <i>Description:</i> Dosing was initiated at 40 mg/day each evening at 8:00pm(-30minutes) for 1 week, with scheduled titration, as medically indicated and tolerated, over the subsequent 2 weeks to 60 mg/day(Visit 3) and 80 mg/day (Visit 4). The maximum allowable dose was 3.7 mg/kg/day and one down-titration step (i.e., 20-mg decrement) was permitted for safety or tolerability reasons. Participants who were unable to tolerate a dose of at least 40 mg/day during the final week were discontinued. Participants were also permitted to adjust the evening dosing time between 6:30 and 9:30pm in 30- or 60-minute increments per week to achieve optimal morning control of observed ADHD symptoms ● <i>Treatment duration:</i> 3 weeks <p>Control</p> <ul style="list-style-type: none"> ● <i>Description:</i> Placebo ● <i>Treatment duration:</i> 3 weeks
Outcomes	<p>ADHD kernesymptomer, observatør/kliniker bedømt, ADHD-RS-IV. Total score. SE</p> <ul style="list-style-type: none"> ● Outcome type: Continuous Outcome ● Lower=better <p>Alvorlige bivirkninger-totalt, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome <p>Frafald pga. bivirkninger. n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome <p>Appetitforstyrrelser, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome <p>Vættab, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome <p>Søvnforstyrrelser, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Judgement Comment: Described as randomized, unclear how
Allocation concealment (selection bias)	Unclear risk	Judgement Comment: Described as double-blinded, unclear how
Blinding of participants and personnel (performance bias)	Unclear risk	Judgement Comment: Described as double-blinded, unclear how
Blinding of outcome assessment (detection bias)	Unclear risk	Judgement Comment: Described as double-blinded, unclear how
Incomplete outcome data (attrition bias)	Low risk	Judgement Comment: Dropouts have been accounted for
Selective reporting (reporting bias)	Low risk	Judgement Comment: No other apparent sources of bias
Other bias	Low risk	Judgement Comment: No other apparent sources of bias

Quinn 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ramtvedt 2013

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Rapport 1985

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Rapport 1987

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Rapport 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Riggs 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Rubinsten 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Samuels 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Schachar 1997a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Schachar 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Schulz 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Schwartz 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Sharp 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Shiels 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Silva 2005a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Silva 2006

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Silva 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Smith 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Smith 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Smithee 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Solanto 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Stein 1996

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Stein 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Stein 2011

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Stoner 1994

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Sumner 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Sunohara 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Swanson 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Swanson 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Swanson 2002a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Swanson 2002b

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Swanson 2004b

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Symons 2007

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Szobot 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Szobot 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tannock 1989

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tannock 1992

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tannock 1993

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tannock 1995a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tannock 1995b

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Taylor 1987

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Taylor 1993

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tervo 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tiresh 1993a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tiresh 1993b

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tourette's Syndrome Study Group 2002

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Tucker 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ullmann 1985

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Ullmann 1986

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Urman 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Van der Meere 1999a

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wallace 1994

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wallander 1987

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Waxmonsky 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Whalen 1990

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wigal 2003

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wigal 2004

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wigal 2013

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wigal 2014

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wigal 2015

Methods	<p>Study design: Randomized controlled trial</p> <p>Study grouping: Parallel group</p>
Participants	<p>Baseline Characteristics</p> <p>Overall</p> <ul style="list-style-type: none"> ● Age: 10.8 ● Male %: 67 ● % on medication: <p>Included criteria: Children and adolescents (male and female) aged 6–18 years at time of consent with an ADHD diagnosis of all subtypes (except Not Otherwise Specified) as de-fined in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) [12] were included if they met defined inclusion and exclusion criteria. ADHD diagnosis was supported by the Schedule for Affective Disorders and Schizophrenia for School-Age Children—Present and Lifetime version (K-SADS-PL) [13]. Recorded baseline ADHD-RS-IV total or subscale scores had to be <math>C_{90}</math>th percentile relative to the general population of children by age and sex at screening or baseline. Patients had to require pharmacological treatment for ADHD</p> <p>Excluded criteria: Exclusion criteria included an Estimated Full Scale intellectual level ≥ 80 using the four-subtest form of the Wechsler Abbreviated Scale of Intelligence (WASITM) [14], and a current primary psychiatric diagnosis of severe anxiety disorder, conduct disorder, psychotic disorder, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, major depressive disorder, bipolar disorder, substance use disorder, chronic tic disorder, or a personal or family history of Tourette's syndrome as defined by the DSM-IV-TR criteria and supported by the K-SADS-PL. Patients with a chronic medical illness (seizure, cardiac disorders, untreated thyroid disease, glaucoma), using monoamine oxidase inhibitors or psychotropic medication within 14 days of screening or another experimental drug or device within 30 days of screening, who had a clinically significant electrocardiogram (ECG) or clinical laboratory abnormality at screening and/or baseline, or who were pregnant or lactating were also excluded from the study.</p> <p>Pretreatment: Most patients were male (67 %) and were predominantly white (69 %) (Table 2). The average age was 10.8 years: 60 children were 6–8 years, 76 were 9–11 years, 63 were 12–14 years, and 31 were 15–18 years.</p>
Interventions	<p>Intervention Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Description: MPH-MLR 10 mg ● Treatment duration: 16 weeks <p>Intervention 2</p> <ul style="list-style-type: none"> ● Description: MPH-MLR 15 mg ● Treatment duration: 16 weeks <p>Intervention 3</p> <ul style="list-style-type: none"> ● Description: MPH-MLR 20 mg ● Treatment duration: 16 weeks <p>Intervention 4</p> <ul style="list-style-type: none"> ● Description: MPH-MLR 40 mg ● Treatment duration: 16 weeks <p>Control</p> <ul style="list-style-type: none"> ● Description: placebo ● Treatment duration: 16 weeks
Outcomes	<p>Alvorlige bivirkninger-totalt, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome <p>Appetitforstyrrelser, n</p> <ul style="list-style-type: none"> ● Outcome type: Dichotomous Outcome

	<p><i>Søvnforstyrrelser, n</i></p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome <p><i>ADHD kernesymptomer, observatør/kliniker bedømt. ADHD-RS-IV. Total score. CHANGE</i></p> <ul style="list-style-type: none"> ● Outcome type: ContinuousOutcome ● Read from graph. SD imputed from Findling 2008
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "During this phase, patients were randomized (1:1:1:1:1) to receive MPH-MLR 10, 15, 20, or 40 mg or placebo following a computer-generated randomization schedule with patients assigned the next random number arranged in an ABCDE block design with each letter representing one of the five treatment groups."
Allocation concealment (selection bias)	Unclear risk	Judgement Comment: Nothing mentioned
Blinding of participants and personnel (performance bias)	Low risk	Judgement Comment: One phase includes the patients being blinded
Blinding of outcome assessment (detection bias)	Unclear risk	Judgement Comment: Nothing mentioned
Incomplete outcome data (attrition bias)	High risk	Judgement Comment: the dropout in each treatment group were not sufficiently specified
Selective reporting (reporting bias)	Low risk	Judgement Comment: Matches study protocol
Other bias	Low risk	Judgement Comment: No other apparent sources of bias

Wigal 2017

Methods	<p>Study design: Randomized controlled trial</p> <p>Study grouping: Parallel group</p>
Participants	<p>Baseline Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Age: 9.9 (1.71) ● Male %: 71.4 ● % on medication: <p>Placebo</p> <ul style="list-style-type: none"> ● Age: 9.3 (1.62) ● Male %: 53.5 ● % on medication: <p>Included criteria: Eligible subjects were males and females 6–12 years of age with a diagnosis of ADHD determined by a psychiatrist, developmental pediatrician, pediatrician, or licensed allied health professional, who were deemed to have the need for pharmacological treatment for ADHD in the judgment of the investigator. Diagnoses were confirmed based on three criteria: positive confirmation of ADHD diagnosis using the Schedule for Affective Disorders and Schizophrenia for School Age Children (K-SADS) (Kaufman et al. 1997) semistructured diagnostic interview at screening by a psychiatrist, psychologist, developmental pediatrician, pediatrician, or licensed clinical social worker, trained and experienced with the K-SADS (visit 1); investigator administered Clinical Global Impressions–Severity (CGI-S) (Guy 1976) score of at least 3 (mildly ill); and an investigator administered ADHD Rating Scale (ADHD-RS-IV) Home Version score in the 90th percentile or greater for gender and age on the hyperactive–impulsive subscale, inattentive subscale, and/or total score at screening or baseline (visit 2)</p> <p>Excluded criteria: Subjects were excluded from the study if they had a current primary psychiatric diagnosis of severe anxiety disorder, conduct disorder, pervasive developmental disorder, eating disorder, obsessive-compulsive disorder, major depressive disorder, bipolar disorder, or other psychiatric disorder, substance abuse disorder, or a personal or family history of Tourette's syndrome. Subjects were also excluded if they had a clinically significant or severe medical illness or condition, including seizure disorder, cardiac disorders or conditions (including severe hypertension), untreated thyroid disease, or a history of HIV or hepatitis B or C infections. Subjects with clinically significant abnormal laboratory results or a positive test for illicit drug use at screening were excluded, as were those with a history of hypersensitivity or lack of efficacy to MPH. Psychotropic agents were prohibited. Sedative hypnotics were prohibited within 24 hours before screening, except sedative hypnotics that had been prescribed as sleep aids (at bedtime only) for at least 30 days before the baseline visit. (Promethazine [one MPH ERCT-treated patient, for viral infection] was the only sedative hypnotic reported in this study.) Pharmacologic treatments for ADHD, including noninvestigational stimulant medications for the control of ADHD, were allowed until 24 hours before the baseline visit for the open-label, dose-optimization period.</p> <p>Pretreatment:</p>
Interventions	<p>Intervention Characteristics</p> <p>Intervention 1</p> <ul style="list-style-type: none"> ● Description: During the open-label period, subjects received MPH ERCT at a starting dose of 20 mg once daily. At weekly intervals during the open-label period (visits 3–8), the dose could be increased, in 10–20 mg/day increments to a maximum dose of 60 mg/day, or decreased to optimize efficacy and tolerability. Dose adjustments were based on clinical judgment of the investigator taking into account all available efficacy and tolerability information. Subjects who could not tolerate 20 mg/day or were unable to achieve a stable dose during the open-label period were discontinued. <p>The randomized, double-blind treatment period included 1 week of double-blind treatment followed by a laboratory</p>

	<p>classroom evaluation (visit 9). Subject received their optimal open label dose.</p> <ul style="list-style-type: none"> ● <i>Treatment duration</i>: 6 weeks open label and 1 week blinded treatment <p>Placebo</p> <ul style="list-style-type: none"> ● <i>Description</i>: Placebo ● <i>Treatment duration</i>: DO
Outcomes	<p>ADHD kernesymptomer, observatør/kliniker bedømt, SKAMP-Combined scores 0,75 hours postdose (visit 9)</p> <ul style="list-style-type: none"> ● Outcome type: ContinuousOutcome <p>Alvorlige bivirkninger-totalt, n</p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome <p>Frafald pga. bivirkninger. n</p> <ul style="list-style-type: none"> ● Outcome type: DichotomousOutcome
Notes	

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization was conducted according to a fixed schedule using a permuted block design stratified by clinical site
Allocation concealment (selection bias)	Low risk	The randomization code was maintained centrally by the clinical supply group, and the study team and investigator site personnel were blinded throughout the study.
Blinding of participants and personnel (performance bias)	Low risk	Blinded
Blinding of outcome assessment (detection bias)	Low risk	Blinded
Incomplete outcome data (attrition bias)	Low risk	No apparent bias. 85 out of 86 completed the one week blinded treatment
Selective reporting (reporting bias)	Low risk	No apparent bias
Other bias	Low risk	No apparent bias

Wilens 2006b

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wilens 2008

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

--	--

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wilens 2010

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wilkison 1995

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wodrich 1998

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Wolraich 2001

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Zeiner 1999

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Zeni 2009

Methods	
Participants	
Interventions	
Outcomes	
Notes	See Storebø et al 2015 "Methylphenidate for children and adolescence with attention deficit hyperactivity disorder" The cochrane library

Risk of bias table

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	
Allocation concealment (selection bias)	Unclear risk	
Blinding of participants and personnel (performance bias)	Unclear risk	
Blinding of outcome assessment (detection bias)	Unclear risk	
Incomplete outcome data (attrition bias)	Unclear risk	
Selective reporting (reporting bias)	Unclear risk	
Other bias	Unclear risk	

Footnotes

Summary of findings tables


Data and analyses

1 Methylphenidate vs control

Outcome or Subgroup	Studies	Participants	Statistical Method	Effect Estimate
1.1 ADHD symptoms, Independent assessor-rated	14	2867	Std. Mean Difference (IV, Random, 95% CI)	-0.63 [-0.82, -0.45]
1.2 ADHD symptoms, Teacher-rated	19	1698	Std. Mean Difference (IV, Random, 95% CI)	-0.77 [-0.90, -0.64]
1.3 ADHD symptoms, Parent-rated	21	2187	Std. Mean Difference (IV, Random, 95% CI)	-0.66 [-0.82, -0.51]
1.4 Oppositional behaviour, Independent assessor-rated.	5	896	Std. Mean Difference (IV, Random, 95% CI)	-0.59 [-0.76, -0.43]
1.5 Oppositional behavior, Teacher-rated	3	227	Std. Mean Difference (IV, Random, 95% CI)	-0.81 [-1.11, -0.52]
1.6 Oppositional behaviour, Parent-rated	3	212	Std. Mean Difference (IV, Random, 95% CI)	-0.64 [-0.95, -0.33]
1.7 Number of serious adverse events	13	2604	Risk Ratio (IV, Random, 95% CI)	1.02 [0.48, 2.17]
1.9 Sleep problems	18		Risk Ratio (IV, Random, 95% CI)	1.94 [1.35, 2.80]
1.10 Anxious	3		Risk Ratio (IV, Random, 95% CI)	1.37 [0.84, 2.25]
1.11 Decreased appetite	19	3957	Risk Ratio (IV, Random, 95% CI)	3.53 [2.64, 4.71]
1.12 Decreased weight	7	1463	Risk Ratio (IV, Random, 95% CI)	4.28 [1.75, 10.46]
1.13 Weight	5	805	Mean Difference (IV, Random, 95% CI)	-1.92 [-2.45, -1.39]
1.14 Quality of life	3	514	Std. Mean Difference (IV, Random, 95% CI)	0.61 [0.42, 0.80]


Figures

Figure 1 (Analysis 1.2)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.2 ADHD symptoms, Teacher-rated.

Figure 2 (Analysis 1.1)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.1 ADHD symptoms, Independent assessor-rated.

Figure 4 (Analysis 1.5)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.5 Oppositional behavior, Teacher-rated.

Figure 5 (Analysis 1.4)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.4 Oppositional behaviour, Independent assessor-rated..

Figure 6 (Analysis 1.3)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.3 ADHD symptoms, Parent-rated.

Figure 8 (Analysis 1.6)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.6 Oppositional behaviour, Parent-rated.

Figure 9 (Analysis 1.7)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.7 Number of serious adverse events.

Figure 11 (Analysis 1.9)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.9 Sleep problems.

Figure 12 (Analysis 1.10)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.10 Anxious.

Figure 13 (Analysis 1.11)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.11 Decreased appetite.

Figure 15 (Analysis 1.12)




Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.12 Decreased weight.

Figure 16 (Analysis 1.13)



Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.13 Weight.

Figure 17 (Analysis 1.14)



Forest plot of comparison: 1 Methylphenidate vs control, outcome: 1.14 Quality of life.